84
Participants
Start Date
August 26, 2016
Primary Completion Date
May 21, 2019
Study Completion Date
January 5, 2021
Golimumab
Participants will receive subcutaneous golimumab intermittently for 52 weeks in double-blind period, where doses will be based on weight and/or body surface area. Participants meeting response criteria at Week 52, may receive golimumab SC for 50 weeks (doses will be based on weight and/or body surface area) in an OL extension period.
Placebo
Matching Placebo to golimumab.
Little Rock
Newport Beach
Sacramento
San Diego
San Francisco
Walnut Creek
Aurora
New Haven
Doral
Gainesville
Atlanta
Columbus
Boise
Chicago
Indianapolis
Lexington
Louisville
Baton Rouge
Baltimore
Boston
Worcester
Morristown
Buffalo
The Bronx
Mentor
Philadelphia
Sioux Falls
Dallas
San Antonio
Schertz
Webster
Seattle
Tacoma
Janssen Research & Development, LLC
INDUSTRY